Evaluation of prognostic scale Thrombolysis In Myocardial Infarction and Killip. An ST-elevation myocardial infarction new scale

García-Paredes, Teresa; Aguilar-Alonso, Eduardo; Arboleda-Sánchez, José Andrés; Vera-Almazán, A.; Arias-Verdu, M. D.; Olea-Jiménez, Victoria; Fuset-Cabanes, M.P.; Sánchez‐Cantalejo, Emilio; Rivera-Fernández, Ricardo

doi:10.1016/j.ajem.2014.08.026

Cited by 8 publications

(7 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although several systems have been used for risk stratification in the patients with STEMI, such as TIMI and GRACE, the sophisticated calculation usually makes them inconvenient to operate at bedside in daily clinical practice [9,10]. Our results suggest that MSI of 1.4 or greater could be used for risk stratification in the patients with STEMI, although a large, more sufficient study is required to demonstrate these findings in the future.…”

Section: Clinical Implicationmentioning

confidence: 70%

“…Risk assessment provides an opportunity to integrate various patient characteristics into a semiquantitative score that can convey an overall estimate of a patient's prognosis; can dictate the acuity, intensity, and location of care; and can provide the patient and family with a more informed sense of potential outcome [8]. At present, several systems of risk stratification such as Thrombolysis In Myocardial Infarction (TIMI) and Globle Register Acute Coronary Events (GRACE) are used, but the sophisticated calculation usually makes them inconvenient to operate at bedside in daily clinical practice [9,10]. Recently, Huang et al [11] suggested that admission SI of 0.7 or greater is a useful predictor for short-term outcomes in the patients with STEMI.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Modified Shock Index is a Predictor for 7-Day Outcomes in Patients With STEMI

Shangguan

et al. 2015

The American Journal of Emergency Medicine

View full text Add to dashboard Cite

Section: Clinical Implicationmentioning

confidence: 70%

Section: Introductionmentioning

confidence: 99%

Modified Shock Index is a Predictor for 7-Day Outcomes in Patients With STEMI

Shangguan

et al. 2015

The American Journal of Emergency Medicine

View full text Add to dashboard Cite

“…Recently, several publications have reported the importance of a multimarker approach to predict long‐term outcome in patients presenting with STEMI . Interestingly, many of these studies only considered available biomarkers derived from blood obtained at admission, and focused on the long‐term instead of short‐term outcome.…”

Section: Discussionmentioning

confidence: 99%

The contemporary value of peak creatine kinase‐MB after ST‐segment elevation myocardial infarction above other clinical and angiographic characteristics in predicting infarct size, left ventricular ejection fraction, and mortality

Hartman

Eppinga

Vlaar

et al. 2016

Clinical Cardiology

View full text Add to dashboard Cite

Background Complex multimarker approaches to predict outcome after ST‐elevation myocardial infarction (STEMI) have only considered a single baseline sample, while neglecting easily obtainable peak creatine kinase and creatine kinase‐MB (CK‐MB) values during hospitalization. Methods We studied 476 patients undergoing primary percutaneous coronary intervention for STEMI and cardiac magnetic resonance imaging (CMRI) at 4‐6 months after STEMI. We determined the association with cardiac biomarkers (peak CK‐MB, peak troponin T, N‐terminal pro‐brain natriuretic peptide), clinical and angiographic characteristics with infarct size, and LVEF, followed by association with mortality in 1120 STEMI patients. Results Peak CK‐MB was the strongest predictor for infarct size (P<0.001, R 2=0.60) and LVEF (P<0.001, R 2=0.40). The additional value of clinical and angiographic characteristics was limited. The optimal peak CK‐MB cutpoints, for differentiation among small (<10% of the left ventricle), moderate (≥10%–<30%), and large infarct size (≥30%), were 210 U/L and 380 U/L, respectively. These cutpoints were associated with 90‐day mortality; the hazard ratio for moderate infarct was 2.99 (95% confidence interval [CI]: 1.51‐5.93, P=0.002) and for large infarct 6.53 (95% CI: 3.63‐11.76, P<0.001). Conclusions Classical peak CK‐MB measured during hospitalization for STEMI was superior to other clinical and angiographic characteristics in predicting CMRI‐defined infarct size and LVEF, and should be included and validated in future multimarker studies. Peak CK‐MB cutpoints differentiated among infarct size categories and were associated with increased 90‐day mortality risk.

show abstract

“…PLR as an index contains both information on platelets and lymphocyte counts, therefore, the combination of increased platelet counts and low levels of lymphocytes can be an indispensable biomarker to predict the severity of inflammation. STEMI poses a serious threat to human life, earlier studies have showed that high PLR is significantly correlated with MACE, LVEF value, [11] diameter of stent implantation, [12] Killip grade in patients [13] with AMI; however, few studies have been conducted for STEMI patients in particular. The CAMI-STEMI score is a practical, simple risk stratification scoring system which does not require blood tests and medical history.…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of platelet/lymphocyte ratio and CAMI-STEMI score for major adverse cardiac events in patients with acute ST segment elevation myocardial infarction after percutaneous coronary intervention

Wang

Peng

2021

Medicine

View full text Add to dashboard Cite

The aim of this study was to investigate the predictive value of the platelet-to-lymphocyte ratio (PLR) and the China Acute Myocardial Infarction registry-ST segment elevation myocardial infarction (CAMI-STEMI) score for major adverse cardiovascular events (MACE) in ST-segment elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention (PCI) within 6 months.We enrolled STEMI patients who received emergency PCI in the First Hospital of Lianyungang from January 2016 to December 2019. The clinical characteristics of the patients, the PLR, and the CAMI-STEMI score were recorded. The MACE included heart failure, nonfatal re-infarction, recurrent angina pain, re-hospitalization for cardiovascular-related illness, repeat PCI, coronary artery bypass grafting, and all-cause mortality. According to the incidence of MACE during the follow-up the patients were divided into the MACE group (96 cases, 24.8%) and the non-MACE group (291 cases, 75.2%).The PLR, 147.62 (121.13–205.20) in MACE group, was 111.19 (90.23–146.42) in the non-MACE group in comparison, the PLR was higher in MACE group than that in non-MACE group (P < .01). Multivariate regression analysis showed that PLR (odds ratio (OR) = 1.007, 95% confidence interval (CI) 1.002–1.012, P < .01) and CAMI-STEMI score (OR = 1.575, 95% CI: 1.311–1.892, P < .01) were independent predictors of MACE. Besides, I-BIL was also an independent predictor of MACE (OR = 1.007, 95% CI: 1.011–1.146, P = .021). Reciever-operating characteristic curve showed that the area under curve of PLR was 0.704 (95%CI 0.644–0.763, P < .001). The cutoff value was 112.6, the sensitivity and specificity were 84.4% and 51.9%, respectively.PLR and CAMI-STEMI scores were independent risk factors of MACE after PCI in STEMI patients.

show abstract

Evaluation of prognostic scale Thrombolysis In Myocardial Infarction and Killip. An ST-elevation myocardial infarction new scale

Cited by 8 publications

References 47 publications

Modified Shock Index is a Predictor for 7-Day Outcomes in Patients With STEMI

Modified Shock Index is a Predictor for 7-Day Outcomes in Patients With STEMI

The contemporary value of peak creatine kinase‐MB after ST‐segment elevation myocardial infarction above other clinical and angiographic characteristics in predicting infarct size, left ventricular ejection fraction, and mortality

Prognostic value of platelet/lymphocyte ratio and CAMI-STEMI score for major adverse cardiac events in patients with acute ST segment elevation myocardial infarction after percutaneous coronary intervention

Contact Info

Product

Resources

About